Combat Atopic Dermatitis—Without the Burn
Spa Business > Medical Spa
Thank you for your inquiry. Please note that the author cannot provide individual medical advice. Also, if you have a customer service question, email customer service at customerservice@skininc.com
Most Popular in Medical Spa
1Top 9 MedSpa Buzzwords
2Tell Me the Truth—Who Can Really Perform Laser Treatments?
3Microneedling Opens Door for Rosacea Relief
4Clients vs. Patients
5How to Select the Right Products for Your Med Spa
6There's an App for That—Previewing Facial Filler Results
7Top 3 Hottest Non-Surgical Treatments of 2018
83 Things You Need to Know About the Global Medical Esthetic Industry
9Skin Care Vs. Surgery: Finding a Moral Code in the MedSpa
10Alan Durkin Puts the 'Ahh' in Med Spa
More efficient atopic dermatitis (AD) treatments are just around the corner, after a long drought of advances compared to innovations in psoriasis care. New biologics and topical agents are receiving a boost in efficacy after studies found them effective in combating AD.
AD typically occurs in children, with only 5% of patients experiencing symptoms for more than 20 years. Parents and younger patients often simply treat the condition with moisturizer, although this method is far from foolproof—furthering the need for new treatments. A common feature of AD is pruritus or itching.
The FDA approved crisaborole ointment (Eucrisa, Pfizer) last December. The phosphodiesterase 4 inhibitor is a topical agent which studies found to work quickly and without the notorious burning sensation of calcineurin inhibitors (with a rate of 4.4% compared to 1.2% with vehicle). 1,522 patients with mild-to-moderate AD from age 2–79 participated in two placebo-controlled trials. After 28 days of treatment, half of the active drug group experienced clear skin.
Dupilumab (Dupixent, Sanofi/Regeneron) is the first biologic approved by the FDA as an option for patients who do not respond to topical agents. The human monoclonal antibody improved AD and pruritus, along with anxiety and depression, in two phase III, randomized trials for moderate-to-severe AD. Dupilumab inhibits signaling of cytokines IL-4 and IL-13, which contribute most to the development of AD.
Read more at dermatologytimes.com (source).
Consumer Demand for Acne Treatments Surges
12/28/2018, Maggie Connelly
Investigational Cream Set to Help Treat Atopic Dermatitis
2/26/2019, Maggie Connelly
Are Blood Tests the Future of Diagnosing Melanoma?
Top 3 Hottest Non-Surgical Treatments of 2018
Rich Girl Face Leaves Clients Boasting About Treatments